52 citations,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
48 citations,
March 1997 in “Veterinary Dermatology” Some cats with sudden hair loss and tiredness might have cancer-related alopecia.
32 citations,
January 2006 in “Acta dermato-venereologica” SACUMAN, a rare condition causing hair loss without clear signs, is often misdiagnosed and needs scalp biopsies for accurate detection.
30 citations,
February 1994 in “Journal of Cutaneous Pathology” A woman's hair loss was initially mistaken for a common hair loss condition but was later found to be caused by breast cancer cells in her scalp.
25 citations,
July 1994 in “Archives of Dermatology” A man's skin condition, pemphigus vulgaris, came back after he was treated with interleukin 2 for cancer.
24 citations,
February 2007 in “International Journal of Dermatology” A woman with cervical cancer had rare scalp metastasis causing a unique type of hair loss.
21 citations,
March 2015 in “Journal of The American Academy of Dermatology” Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.
16 citations,
March 2019 in “Actas Dermo-Sifiliográficas” Vitamin D is important for skin health and can affect various skin diseases.
10 citations,
September 2016 in “Journal of cutaneous medicine and surgery” Patients on dabrafenib and trametinib for melanoma often experience skin side effects.
3 citations,
June 2018 in “Bioorganic & medicinal chemistry” Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.
March 2011 in “European Urology Supplements” Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.
August 2010 in “Journal of The American Academy of Dermatology” The document explains the diagnosis and characteristics of woolly hair nevus and alopecia neoplastica.
9 citations,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
78 citations,
June 2005 in “Annals of oncology” Cetuximab can cause excessive eyelash growth.
9 citations,
June 2013 in “Australasian Journal of Dermatology” Infliximab improved skin and bowel symptoms in Crohn's disease but caused side effects and the disease returned after stopping treatment.
June 2015 in “Reactions Weekly” A man developed alopecia areata after starting cancer treatment with vandetanib.
39 citations,
June 2019 in “Frontiers in Endocrinology” Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
January 2017 in “Elsevier eBooks” Radiation therapy for cancer often causes skin problems like redness, dryness, and pain.
82 citations,
March 2013 in “PLoS ONE” Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.
30 citations,
August 2010 in “American Journal of Clinical Dermatology” Cetuximab can cause eyelash growth, which is rare but manageable.
21 citations,
February 2013 in “Clinics in Dermatology” New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.
19 citations,
October 2016 in “Journal of oncology pharmacy practice” A cancer patient's hair became permanently curly after treatment with nivolumab.
3 citations,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
3 citations,
August 2019 in “Journal of Cancer Research and Therapeutics” Cetuximab can cause unusual hair growth and hair loss.
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
108 citations,
December 2003 in “Clinical breast cancer” PLD is an effective and safer alternative for treating breast cancer.
60 citations,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
38 citations,
July 1998 in “Journal of surgical oncology” A woman with breast cancer developed a rare condition causing excessive fine hair growth on her face and body.
30 citations,
March 2007 in “Expert opinion on drug safety” Cetuximab often causes skin rashes, and managing these is important for cancer treatment.